Polymeric oncolytic adenovirus for cancer gene therapy

J Control Release. 2015 Dec 10;219:181-191. doi: 10.1016/j.jconrel.2015.10.009. Epub 2015 Oct 23.

Abstract

Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research.

Keywords: Active targeting; Cancer gene therapy; Clinical trials; Oncolytic Ad/polymer hybrid vector; Oncolytic adenovirus; Systemic administration; Tumor microenvironment targeting.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenoviridae* / chemistry
  • Animals
  • Genetic Therapy*
  • Genetic Vectors
  • Humans
  • Neoplasms / therapy*
  • Oncolytic Virotherapy / methods
  • Oncolytic Viruses* / chemistry
  • Polymers* / chemistry
  • Static Electricity
  • Tumor Microenvironment

Substances

  • Polymers